Product Description
Sanofi was developing aav2-sflt01, an injectable VEGF Antagonist for patients with Age-Related Macular Degeneration. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01024998)
Mechanisms of Action: VEGF Antagonist
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Wet Macular Degeneration|Retinal Degeneration|Retinal Neovascularization
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01024998 |
sFLT01-AMD-00106 | P1 |
Completed |
Retinal Degeneration|Wet Macular Degeneration|Retinal Neovascularization |
2014-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|